Pimozide
2 NDCs across 1 manufacturer|2 Generic,0 Brand
Pimozide is used to treat huntington disease, psychotic disorders and tourette syndrome, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Jul 31, 1984, and the first generic was approved Sep 28, 2015. FDA's Orange Book lists 4 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $1 million on Pimozide across 11,000 claims for 1,995 beneficiaries.
Pimozide is available as 2 NDCs from 1 manufacturer (2 generic, 0 brand), with NADAC prices from $1.23 to $1.64 per EA — a 33% difference between cheapest and most expensive. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
2
2G / 0B
Manufacturers
1
competing in market
Price Spread
$1.23 – $1.64
per EA
7d Activity
avg -1.1% WoW · of 2 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Endo USA Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Typical Antipsychotic class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
1 manufacturer producing PIMOZIDE
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
PIMOZIDE 2 MG TABLET | $1.6400 per EA | -2.72% |
PIMOZIDE 1 MG TABLET | $1.2349 per EA | +0.44% |
Frequently Asked Questions
What is Pimozide used to treat?
Pimozide is used to treat huntington disease, psychotic disorders and tourette syndrome, per the National Library of Medicine's MED-RT classification.
When did Pimozide become available as a generic?
FDA approved the first generic Pimozide (ANDA) on Sep 28, 2015. The Orange Book currently lists 4 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Pimozide?
In 2024, Medicare Part D spent $1 million on Pimozide across 11,000 claims for 1,995 beneficiaries.
How many Pimozide products are on the market?
The Pimozide drug market contains 2 NDCs from 1 manufacturer — 2 generic and 0 brand products.
What is the price range for Pimozide?
NADAC reference prices for Pimozide range from $1.2349 to $1.6400 per EA — a 33% difference between cheapest and most expensive.
Which manufacturers make Pimozide?
1 manufacturer lists Pimozide in NADAC. Ranked by number of NDCs, the largest are Endo USA Inc. (2).
How has the price of Pimozide changed recently?
Over the past 7 days, 1 Pimozide NDC rose and 1 fell, with a market-wide average change of -1.1%.